The 2018 AHA/ACC cholesterol guideline executive summary introduced risk enhancers, coronary artery calcium scoring for shared decision-making, and LDL-cholesterol thresholds for escalating therapy to PCSK9 inhibitors. The guideline shifted the paradigm from fixed-dose statin therapy toward personalized, risk-based LDL management.
